Gemzik B, Parkinson A
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417.
Arch Biochem Biophys. 1992 Aug 1;296(2):366-73. doi: 10.1016/0003-9861(92)90586-l.
5 alpha-Dihydrotestosterone, the principal androgen mediating prostate growth and function in the rat, is formed from testosterone by steroid 5 alpha-reductase. The inactivation of 5 alpha-dihydrotestosterone involves reversible reduction to 5 alpha-androstane-3 beta,17 beta-diol by 3 beta-hydroxysteroid oxidoreductase followed by 6 alpha-, 7 alpha-, or 7 beta-hydroxylation. 5 alpha-Androstane-3 beta,17 beta-diol hydroxylation represents the ultimate inactivation step of dihydrotestosterone in rat prostate and is apparently catalyzed by a single, high-affinity (Km approximately 0.5 microM) microsomal cytochrome P450 enzyme. The present studies were designed to determine if 5 alpha-androstane-3 beta,17 beta-diol hydroxylation by rat prostate microsomes is inhibited by agents that are known inhibitors of androgen-metabolizing enzymes. Inhibitors of steroid 5 alpha-reductase (4-azasteroid analogs; 10 microM) or inhibitors of 3 beta-hydroxysteroid oxidoreductase (trilostane, azastene, and cyanoketone; 10 microM) had no appreciable effect on the 6 alpha-, 7 alpha-, or 7 beta-hydroxylation of 5 alpha-androstane-3 beta,17 beta-diol (10 microM) by rat prostate microsomes. Imidazole-type antimycotic drugs (ketoconazole, clotrimazole, and miconazole; 0.1-10 microM) all markedly inhibited 5 alpha-androstane-3 beta,17 beta-diol hydroxylation in a concentration-dependent manner, whereas triazole-type antimycotic drugs (fluconazole and itraconazole; 0.1-10 microM) had no inhibitory effect. The rank order of inhibitory potency of the imidazole-type antimycotic drugs was miconazole greater than clotrimazole greater than ketoconazole. In the case of clotrimazole, the inhibition was shown to be competitive in nature, with a Ki of 0.03 microM. The imidazole-type antimycotic drugs inhibited all three pathways of 5 alpha-androstane-3 beta,17 beta-diol hydroxylation to the same extent, which provides further evidence that, in rat prostate microsomes, a single cytochrome P450 enzyme catalyzes the 6 alpha-, 7 alpha-, and 7 beta-hydroxylation of 5 alpha-androstane-3 beta,17 beta-diol. These studies demonstrate that certain imidazole-type compounds are potent, competitive inhibitors of 5 alpha-androstane-3 beta,17 beta-diol hydroxylation by rat prostate microsomes, which is consistent with the effect of these antimycotic drugs on cytochrome P450 enzymes involved in the metabolism of other androgens and steroids.
5α-双氢睾酮是介导大鼠前列腺生长和功能的主要雄激素,它由睾酮经甾体5α-还原酶生成。5α-双氢睾酮的失活过程包括经3β-羟基类固醇氧化还原酶可逆性还原为5α-雄甾烷-3β,17β-二醇,随后进行6α-、7α-或7β-羟基化。5α-雄甾烷-3β,17β-二醇的羟基化是双氢睾酮在大鼠前列腺中最终的失活步骤,显然由一种单一的、高亲和力(Km约为0.5微摩尔)的微粒体细胞色素P450酶催化。本研究旨在确定大鼠前列腺微粒体对5α-雄甾烷-3β,17β-二醇的羟基化是否受到已知雄激素代谢酶抑制剂的抑制。甾体5α-还原酶抑制剂(4-氮杂甾体类似物;10微摩尔)或3β-羟基类固醇氧化还原酶抑制剂(曲洛司坦、氮杂替烯和氰酮;10微摩尔)对大鼠前列腺微粒体对5α-雄甾烷-3β,17β-二醇(10微摩尔)的6α-、7α-或7β-羟基化没有明显影响。咪唑类抗真菌药物(酮康唑、克霉唑和咪康唑;0.1 - 10微摩尔)均以浓度依赖性方式显著抑制5α-雄甾烷-3β,17β-二醇的羟基化,而三唑类抗真菌药物(氟康唑和伊曲康唑;0.1 - 10微摩尔)没有抑制作用。咪唑类抗真菌药物的抑制效力排序为咪康唑>克霉唑>酮康唑。就克霉唑而言,其抑制作用显示为竞争性,Ki为0.03微摩尔。咪唑类抗真菌药物对5α-雄甾烷-3β,17β-二醇羟基化的所有三条途径的抑制程度相同,这进一步证明,在大鼠前列腺微粒体中,一种单一的细胞色素P450酶催化5α-雄甾烷-3β,17β-二醇的6α-、7α-和7β-羟基化。这些研究表明,某些咪唑类化合物是大鼠前列腺微粒体对5α-雄甾烷-3β,17β-二醇羟基化的强效竞争性抑制剂,这与这些抗真菌药物对参与其他雄激素和甾体代谢的细胞色素P450酶的作用一致。